You are here

Advisory Committee Recommends Reintroduction of Tysabri to Market

GAITHERSBURG, Md.--(BUSINESS WIRE)--March 8, 2006--Biogen Idec (NASDAQ: BIIB - News) and Elan Corporation, plc (NYSE: ELN - News) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend reintroduction of TYSABRI® (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS).

The Committee's recommendation is advisory to the FDA, and the agency is not bound by this recommendation. The FDA has designated TYSABRI for Priority Review, a status for products that are considered to be significant therapeutic advancements over existing therapies that address an unmet medical need. Biogen Idec and Elan will continue to work closely with the FDA in the weeks ahead with the goal of making TYSABRI available. Discussions with FDA will include, among other things, finalizing the details of the TYSABRI risk management plan. The companies anticipate action by the FDA by March 29, 2006.

Source: Biogen Idec and Elan Corporation

Recent Headlines

Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens
Primary Immunodeficiencies Affect 250,000 People in U.S.
More Than 25% of Patients Responded to Xpovio/Dexamethasone Combo
Attacks Cancerous Cells, Leaves Healthy Tissues Alone
Moderates Pre-diabetes Progression, Reduces Cholesterol Levels
​NCI Study: Radioactive Iodine Associated With Solid Tumors
Old Chemo Drug at High Doses Goads Immune System to Fight Lymphoma
Most Believe Cost is Worthwhile, Could Bring About Cures